RxDoctor Payments Data

Kunal Brahmbhatt, MD

Interventional Cardiology · Passaic, NJNPI 1083059158

Payments from drug & device makers

$13,647in general payments, 2019–2025

Across 238 payments — averaging $57.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abiomed$2K
  • Penumbra, Inc.$1K
  • Edwards Lifesciences$957
  • Abbott$944
  • Cardiovascular Systems Inc.$651
  • plus $4K from 29 others

What the payments were for

  • Travel & lodging$2,74920%
  • Food & beverage$10,79879%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,647 in reported general payments places this provider in the 60th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,232,863
Medicare patients
1,372
Services billed
4,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan52$69,806
EliquisApixaban63$54,937
FarxigaDapagliflozin Propanediol21$32,346
JardianceEmpagliflozin19$31,514
BrilintaTicagrelor32$25,145
XareltoRivaroxaban19$14,206
JanuviaSitagliptin Phosphate14$8,715
Atorvastatin Calcium229$3,028
Rosuvastatin Calcium80$1,857
Losartan Potassium177$1,698
ClopidogrelClopidogrel Bisulfate117$1,479
Metoprolol Succinate126$1,319
Amlodipine Besylate157$1,089
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide47$614
Cilostazol34$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$338$69,80652 claims
AstraZenecaFarxiga, Brilinta$207$57,49153 claims
PfizerEliquis$51$54,93763 claims
Boehringer IngelheimJardiance$23$31,51419 claims
Johnson & JohnsonXarelto$14$14,20619 claims
MerckJanuvia$388$8,71514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Passaic

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →